DMK PHARMACEUTICALS Corp: Nasdaq/NYSE listing notice — DMK Pharmaceuticals receives Nasdaq delisting notice for bid price non-compliance

DMK PHARMACEUTICALS Corp

Received Nasdaq notice on Oct 4, 2023 for failing $1.00 minimum bid price (Rule 5550(a)(2)).
180-day compliance period until April 1, 2024; must close at $1.00+ for 10 consecutive days.
If not cured, may be eligible for an additional 180-day period if other listing standards are met.
Company will monitor bid price and consider available options to regain compliance.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

DMK PHARMACEUTICALS Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

armaceuticals Corporation (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the $1.00 minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The Nasdaq Capital Market. Based on the closing bid price of the Company’s common stock for at least 30 consecutive business days before receipt of the Notice, the Company no longer meets the minimum bid price requirement of the Rule. This notice has

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001387131-23-012033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.